INTRODUCTION
Numerous clinical syndromes have been reported in association with hepatitis C virus (HCV) infection. Some are well established while others remain a speculation (Table  1) [1] , Fourteen to seventy percent of patients with HCV have detectable cryoglobulins in their serum even in the absence of rash, weakness or arthralgias [1] , whereas 50-90% of patients with mixed cryoglobulinaemia are reported to have HCV infection [2] . It is suggested that approximately 10% of type II mixed cryoglobulinaemiae can evolve into malignant lymphoma several years after diagnosis.
Epidemiological studies from Europe, Japan and North America also implicate that HCV plays a role in the pathogenesis of non-Hodgkin lymphomas (NHL) [3] [4] [5] [6] [7] . HCV infection is detectable in a signifi cant proportion of NHL (14-52%), nonetheless, it has not been confi rmed [8] .
A 50-fold elevation in the risk for NHL of the liver or salivary glands has been reported in an Italian case-control study, which is greater than the relative risk of hepatocellular carcinoma. The relative risk for NHL of other sites is increased about 4-fold [9] . An association between multiple myeloma (MM) and chronic HCV infection has been suggested by some epidemiological studies [2, 9] .
CASE REPORT
The authors report a case of a 50 year-old woman with chronic HCV infection who has been followed up since 1998 due to high viral load (13.47 MEq/mL), genotype 1b and moderately elevated liver function tests (LFTs). The patient received treatment of chronic backache and tonsillectomy prior to admission to our hospital. Laboratory data and liver biopsy revealed moderate activity (grade 5/18, stage I). In April 1999, one-year interferon therapy (3x3ME/wk) was initiated. HCV-RNA became negative with normalization of the LFTs. However, the
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An association between chronic hepatitis C virus (HCV) infection and essential mixed cryoglobulinaemia and nonHodgkin lymphoma (NHL) has been suggested. However, a causative role HCV in these conditions has not been established. The authors report a case of a 50 year-old woman with chronic hepatitis C (CHC) who has been followed up since 1998 due to a high viral load, genotype 1b and moderately elevated liver function tests (LFTs). Laboratory data and liver biopsy revealed moderate activity (grade: 5/18, stage: 1/6). In April 1999, one-year interferon therapy was started. HCV-RNA became negative with normalization of LFTs. However, the patient relapsed during treatment. In September 2002, the patient was admitted for chronic back pain. A CT examination demonstrated degenerative changes. In March 2003, multiple myeloma was diagnosed (IgG-kappa, bone marrow biopsy: 50% plasma cell infi l). MRI revealed a compression fracture of the 5 th lumbar vertebral body and an abdominal mass in the right lower quadrant, infi ltrating the canalis spinalis. Treatment with vincristine, adriamycin and dexamethasone (VAD) was started and bisphosponate was administered regularly. In January 2004, after six cycles of VAD therapy, the multiple myeloma regressed. Thalidomide, as a second line treatment of refractory multiple myeloma (MM) was initiated, and followed by peginterferon-α2b and ribavirin against the HCV infection in June. In June 2005, LFTs returned to normal, while HCV-RNA was negative, demonstrating an end of treatment response. Although a pathogenic role of HCV infection in malignant lymphoproliferative disorders has not been established, NHL and possibly MM may develop in CHC patients, supporting a role of a complex follow-up in these patients. In April 2004, she was admitted to the Haematological Department for paraparesis. Laminectomy (Th VII-IX) with myelon decompression and tumor resection was performed. Therapy was amended with thalidomide (100mg o.d.) orally. In August, repeated CT scans demonstrated compression fractures at L5 and S2 accompanying narrowing of the spinal canal at L5. In September, due to worsening of the paraparesis, a second laminectomy was performed (L5-S1) followed by insertion of a stabilizing prosthesis (L4-S1).
In June 2004, weekly peginterferon-α2b (1.5μg/kg) and 800mg ribavirin (daily) were prescribed (HCV PCR 145000 IU/mL, Roche TaqMan). No further dose adjustment was necessary. The LFTs became normal and PCR returned negative after three months of therapy, indicating an early viral response (EVR). In June 2005, the LFTs were normal with a negative HCV-PCR, demonstrating an end of treatment response (ETR).
DISCUSSION
In recent years, major advances have been made in the treatment of HCV infection with the sustained response rate of 52-63% achieved [11] [12] [13] . A major disadvantage in Hungary is that the hard-to-treat genotype 1 is almost universal (90-95%) and occurs much more frequently compared to that in other European countries [13, 14] . Apart from hepatocellular carcinoma, HCV infection is also associated with various extrahepatic diseases, including mixed cryoglobulinaemia and NHL. Fourteen to seventy percent of patients with HCV have detectable cryoglobulins in their serum [1, 2] , while 50-90% of patients with mixed cryoglobulinaemia are reported to have HCV infection.
Epidemiological case-control studies from the 1990s suggest that chronic HCV infection is associated with the development of NHL. It was reported that 9 % and 11.5% of NHL patients are HCV-antibody positive [15, 16] . Germanidis et al [4] investigating 201 NHL patients and found that the prevalence of HCV infection is 2-fold higher than that in controls [4] . More recent studies have further confi rmed this fi nding. A Japanese study showed that 17% of patients with B-cell NHL are HCV-antibody positive compared to 6.6% of controls [6] . Moreover, an East European study [7] reported that 6 out of 42 (24.3%) NHL patients are HCV-antibody positive. In contrast, Rabkin et al [8] investigated the stored sera of 57 NHL patients, 24 MM patients and fourteen Hodgkin's disease patients, and found that only four patients are HCVantibody positive.
An association between chronic HCV infection and MM is also found in epidemiological studies. Gharagozloo et al [2] showed that HCV antigens are detectable in 11% of patients with MM, 69% of patients with essential mixed cryoglobulinaemia and 4.3% of patients with NHL, using recombinant immunoblot assay (RIBA) and enzyme-linked immunosorbent assay (ELISA). Another study revealed that HCV infection is found in 32% of MM patients [10] . The former is associated with 4.3-fold risk for MM.
The possible mechanism by which HCV infection leads to stimulation of B cells is starting to unravel. It is well documented that HCV infection, as observed in our case, usually precedes NHL by many years [9] . Hepatitis C is lymphotropic and may replicate in lymphocytes and hepatocytes [17] . The second portion of the HCV envelope (E2 protein) binds to CD81 [18] , suggesting that this phenomenon is associated with CD19 and CR2 as well as MHC class II molecules on lymphocytes. The binding of CD81 to B cells can activate this complex, which lowers the antigen threshold necessary for antibody stimulation, thus rendering the B cell hyper-responsive. Sequencing of the antigen-binding region of immunoglobulin produced by malignant lymphocytes demonstrates that it has a high degree of homology to both antibodies specific for E2, as well as the antibodies produced by B cells that secrete RF. Furthermore, 88% of patients with HCV infection and cryoglobulinaemia demonstrate over-expression [t (14, 18) translocation] of the anti-apoptotic bcl-2 gene, compared with 8% of patients with HCV infection, 2% of patients with other liver diseases, and 3% of individuals with other rheumatoid disorders, which cause enhanced B cell survival [19] . In addition, over-expression of NF-kB has been reported in lymphocytes and liver samples of patients with chronic HCV infection and those with NHL [20, 21] . This is an important fi nding, as NF-kB plays a key role in virus-induced lymphomagenesis. Mutations of the NFkB gene are common in lymphoid malignancies [22] and alterations of NF-kB could initiate changes in downstream regulatory pathways. A second mutation (e.g. myc, NF-kB) could possibly initiate the progression to lymphoma [23] .
In conclusion, although a pathogenic role of HCV infection in malignant lymphoproliferative disorders has not been established, NHL and possibly MM may develop in cases of CHC, supporting the need for a complex follow-up in these patients.
